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Abstract
Each B-cell receptor consists of a pair of heavy and light chains. High-throughput sequencing can
identify large numbers of heavy- and light-chain variable regions (VH and VL) in a given B-cell
repertoire, but information about endogenous pairing of heavy and light chains is lost after bulk
lysis of B-cell populations. Here we describe a way to retain this pairing information. In our
approach, single B cells (>5 × 104 capacity per experiment) are deposited in a high-density
microwell plate (125 pl/well) and lysed in situ. mRNA is then captured on magnetic beads, reverse
transcribed and amplified by emulsion VH:VL linkage PCR. The linked transcripts are analyzed by
Illumina high-throughput sequencing. We validated the fidelity of VH:VL pairs identified by this
approach and used the method to sequence the repertoire of three human cell subsets—peripheral
blood IgG+ B cells, peripheral plasmablasts isolated after tetanus toxoid immunization and
memory B cells isolated after seasonal influenza vaccination.
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Next-generation sequencing of immunoglobulin variable region and T-cell receptor
repertoires is providing information that is key to understanding adaptive immune responses
and to diagnostic and therapeutic applications1–6. However, existing immune repertoire
sequencing technologies yield data on only one of the two chains of immune receptors and
thus cannot provide information about the identity of immune receptor pairs encoded by
individual B or T lymphocytes2,7,8. Sequence analysis of VH:VL pairs is currently done by
microtiterwell sorting of individual B cells followed by single-cell RT-PCR (scRT-PCR)
and Sanger sequencing8–15; however, at most a few hundred VH:VL pairs (a number
dwarfed by the enormous size of the human antibody repertoire) are identified by means of
scRT-PCR11–14. Microfluidic methods for RT-PCR and the sequencing of two or more
genes (e.g., using the Fluidigm platform16) have so far been limited to only 96 wells per run
and require complex, proprietary instrumentation. As a result, comprehensive analysis of
paired VH:VL gene family usage and somatic hypermutation frequency has been elusive.
Here we report the development, validation and application of an accessible and scalable
technology for the high-throughput sequencing of VH:VL pairs from individual human B
lymphocytes. We used this technology to determine the VH:VL repertoires of several human
B-cell subpopulations of particular interest, namely peripheral class-switched B cells in
healthy individuals, memory B cells after influenza vaccination and antigen-specific
plasmablasts after tetanus toxoid (TT) immunization. We applied this technology to discover
high-affinity, antigen-specific human antibodies from the sequenced plasmablasts.
In this approach, a population of sorted B cells was deposited by gravity into 125-pl wells
molded in polydimethylsiloxane (PDMS) slides (Fig. 1). Each slide contained 1.7 × 105
wells; four slides processed concurrently accommodated 68,000 lymphocytes at a ≥1:10
cell/well occupancy, which gave at least a 95% probability of there being only one cell per
well based on Poisson statistics. Poly(dT) magnetic beads with a diameter of 2.8 μm were
deposited into the microwells at an average of 55 beads/well and the slides were covered
with a dialysis membrane. Subsequently, the membrane-covered slides were incubated with
an optimized cell lysis solution containing 1% lithium dodecyl sulfate that resulted in
complete cell lysis within <1 min (Supplementary Video 1). The mRNA annealed to the
poly(dT) magnetic beads, which were then collected, washed and emulsified with primers,
reverse transcriptase and thermostable DNA polymerase to carry out reverse transcription
followed by linkage PCR (Supplementary Fig. 1). The two-step capture and amplification
process (Fig. 1) was necessary because single-compartment cell lysis followed by RT-PCR
has not proven feasible in volumes ≤5 nl because of inhibition of the reverse transcription
reaction by cell lysate constituents. In addition, performing VH: VL linkage in emulsion
droplets containing single cells would necessitate cell entrapment, lysis, reverse
transcription and in situ –linkage PCR that can only be done in microfluidic devices, a
strategy that requires extensive infrastructure and has been reported to have limited
throughput at ≤300 cells per run17. PCR amplification generated an ∼850–base pair (bp)
linked VH:VL DNA product composed of (from 5′ to 3′) the N-terminal end of CH1, the VH,
a linker region, the VL and the N terminus of Cκ or Cλ (Supplementary Fig. 1). The most
informative 500 bp of this fragment, which encompassed the complementarity determining
regions (CDR-H3 and CDR-L3), was then sequenced on a long-read next-generation
sequencing platform such as the 2 × 250 Illumina MiSeq (which also provided the
framework region FR3 and FR4 sequences and constant region N termini amino acid
sequences that can be used for isotype assignment). If FR1 to CDR2 region sequences were
also desired, the VH and VL gene repertoires were analyzed by separate 2 × 250-bp
sequencing runs. This latter step was required because of read-length limitations with
existing technology; whereas single-molecule sequencing techniques allow for longer reads,
the error rate is too high to enable robust classification of VH:VL sequences.
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We employed the methodology of Figure 1 to determine the VH:VL repertoire of three
different B-cell populations of relevance to human immunology and antibody discovery.
First, we isolated IgG+ B cells from fresh blood donated by a healthy individual. We spiked
61,000 IgG+ B cells with immortalized IM-9 lymphoblast cells (to ∼4% of total mixture)
that express known VH and VL sequences as an internal control. We analyzed these cells in
four PDMS slides (6.8 × 105 total wells). After 2 × 250 MiSeq sequencing, we clustered the
CDR-H3 regions based on 96% sequence identity, consistent with the established error rate
of the MiSeq platform, to determine the number of unique clones recovered from this human
sample. A total of 2,716 unique pairs were thus identified (Supplementary Table 1). The
spiked IM-9 heavy chain overwhelmingly (78-fold above background) paired with its known
light chain. A heat map shows frequencies of pairing between VH and VL segments of
different germline families in the class-switched IgG+ cell repertoire (Fig. 2a). A second
IgG+ repertoire analysis was done using B cells from another anonymous individual; this
analysis identified 2,248 unique CDR-H3 from 47,000 IgG+ cells, and the IM-9 control
spike again demonstrated high pairing accuracy (125-fold above background;
Supplementary Fig. 2 and Supplementary Table 2). Several V gene families (e.g., IGHV7;
IGKV5, 6, and 7; IGLV4, 10, and 11) are expressed at very low frequencies in the human
immune repertoire3,18. We detected VH:VL pairs containing these rare families, indicating
that this technique can identify rare B-cell clones present at physiological levels together
with much more abundant clones (e.g., the much more highly used IGHV3 or IGHV4
families; Fig. 2a and Supplementary Fig. 2). Interestingly, the VH:VL germline pairing
frequencies were highly correlated between the two individuals (Spearman rank correlation
coefficient = 0.804; P < 10−29); the most highly transcribed heavy chain genes (IGHV3,
IGHV4 and IGHV1 families) paired most frequently with the most highly transcribed light
chain genes (IGKV1, IGKV3, IGLV1 and IGLV2 families). However, putative differences
in IgG+ VH:VL germline pairing frequencies between the two individuals were also evident.
In a separate experiment, human plasmablasts (CD19+CD3− CD14−CD38++CD27++CD20−)
from a healthy volunteer were collected 7 d after TT immunization, sorted for surface
antigen binding and then frozen12. After thawing, ∼400 recovered cells were spiked with
the immortalized ARH-77 cell line as an internal control and seeded onto a single PDMS
slide (1.7 × 105 total wells). In this instance, 86 unique primary CDR-H3:CDR-L3 pairs
were identified, and the ARH-77 control spike demonstrated high pairing accuracy (Fig. 2b
and Supplementary Table 1). We expressed ten of the identified VH:VL pairs as IgG proteins
in HEK293K cells. As revealed by competitive enzyme-linked immunosorbent assay
(ELISA), all ten antibodies showed specificity for TT and bound TT with high affinity (0.1
nM ≤ KD ≤ 18 nM; Table 1; antibody sequences provided in Supplementary Data). Whereas
certain VH chains can pair promiscuously with multiple VLs to yield functional antibodies, it
is statistically implausible that 10/10 antibodies could display nM and sub-nM affinities for
TT merely as a consequence of fortuitous VH: VL pairing. For comparison, 10–15% of
antibodies generated by random pairing of VH genes with a small set of enriched VL genes
were antigen-specific19,20.
Finally, we compared the VH:VL pairings identified using this high-throughput approach to
those identified using the established single-cell sorting method11,21; this experiment was
conducted in a double-blinded manner. Peripheral CD19+CD3−CD27+CD38int memory B
cells were isolated from a healthy volunteer 14 d after vaccination with the 2010-2011
trivalent FluVirin influenza vaccine21. For the scRT-PCR analysis, 168 single B cells were
sorted into four 96-well plates, and 168 RT and 504 nested PCR reactions were carried out
individually to separately amplify the VH and VL (κ and λ) genes. DNA products were
resolved by gel electrophoresis and sequenced to yield a total of 51 VH:VL pairs, of which
50 were unique. A separate B-cell aliquot from the same individual was frozen at −80 °C
and later thawed and processed using the new high-throughput approach described here.
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Two PDMS slides (3.4 × 105 total wells) were used, and the sample was spiked with IM-9
cells to confirm pairing accuracy (Supplementary Table 1). A total of 240 unique CDR-
H3:CDR-L3 pairs were recovered (Fig. 2c). Four CDR-H3 sequences detected in the high-
throughput pairing set were also observed in the single-cell RT-PCR analysis. A blinded
analysis revealed that CDR-H3:CDR-L3 pairs isolated by the two approaches were in
complete agreement (Supplementary Table 3, sequences provided in Supplementary Data
and repertoire comparisons in Supplementary Fig. 3). Further, the one VH:VL pair detected
in more than one of the 51 cells analyzed by single-cell RT-PCR was also detected in the
aliquot processed by the new high-throughput approach (clone 2D02 was observed in two
cells by scRT-PCR, Supplementary Table 3); these findings suggest that this B-cell clone
may have undergone a great deal of expansion. The 46 VH genes that were each observed
only once by single-cell RT-PCR but that were not detected in the aliquot processed by our
high-throughput approach presumably represent unique or very low abundance B-cell
clones, as expected given the great degree of V gene diversity normally found in human
peripheral memory B cells.
In these experiments the control cell lines spiked into each aliquot of primary B cells were
selected to approximate the levels of heavy chain and light chain transcription in that
particular primary B-cell subpopulation. For example, the ARH-77 cell line expressed high
levels of heavy chain and light chain transcripts and therefore was spiked into plasmablast
populations that also express abundant heavy chain and light chain transcripts; in contrast,
the IM-9 B lymphoblast cell line, which expresses lower levels of heavy chain and light
chain transcripts, was spiked into memory B-cell populations. Known VH and VL sequences
from spiked-in control cell lines were used to evaluate the frequency of non-native pairings,
that is, the false discovery rate (FDR). The FDR, determined from the mispairing of spiked-
in control VH and VL chains, was commensurate with the probability of coincident cells per
well, which in turn is dictated by cell seeding density and follows Poisson statistics (Online
Methods and Supplementary Table 4). The FDR revealed by the mispairing frequency of
control cell lines represents the upper bound of the FDR, as the control cell lines were
introduced at levels over tenfold higher than the levels at which even a very highly expanded
B-cell clone might be present in a biological sample in humans. Although currently VH:VL
pairing efficiency in memory B-cell populations is relatively modest (Fig. 2 and
Supplementary Fig. 2), efforts to further improve efficiency are under way.
The high-throughput VH:VL pairing technique described here requires one emulsion RT-
PCR reaction, followed by nested PCR, sequencing and bioinformatic analysis. The entire
process from B-cell isolation to the generation of VH:VL heat maps can be completed by a
single investigator in 10 research hours over the course of 4 d (which includes 3 d for gene
sequencing). For example, the work required to recover 2,716 unique VH:VL pairs from a
sample of IgG+ peripheral B cells (Fig. 2a) was completed by a single researcher in 10 h and
cost $550. Analysis of 2,700 cells using established optimal single-cell RT-PCR protocols
would have required >10 weeks of effort by an experienced technician and >$25,000 in
reagent and sequencing costs11.
Because only sequences of up to 500 bp can be accurately determined with current Illumina
next-generation sequencing technology, our method detects the different antibody
clonotypes (antibodies comprising the same CDR-H3:CDR-L3) but cannot yet distinguish
somatic variants originating from clonally related B cells that contain upstream mutations
between FR1 and CDR2 regions. However, this method distinguished nearly identical but
distinct CDR3 regions, as indicated by B-cell clones 2D02 and 3D05, which express light
chain CDR3s that differ by only two nucleotides (Supplementary Table 3). Rapid advances
in next-generation sequencing read-length and quality will likely enable upstream somatic
variant analysis in the near future.
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We used PCR amplification primers targeted to the FR1 region of heavy and light chains
(primers reported in Supplementary Tables 5–7). In some chronic infections (e.g., HIV),
constant antigen exposure can generate antibodies that are highly mutated in all regions
including the FR1 region, and therefore amplification with FR1-specific primers can bias the
repertoire. In these cases, such bias can be readily circumvented by using primers that
anneal to the leader peptide22.
Finally, we note that the analysis reported here focused on the light chain that was the
dominant light chain paired with a particular VH. There are known, albeit rare, instances in
mice where one heavy chain can be found paired with more than one light chain23.
Bioinformatic analysis might discriminate between biologically relevant VH:VL pairs of one
heavy chain with multiple light chains and false pairings that might result from multiple
cells seeded into the same well of the experimental device; false pairings can be flagged
because coincident cells 1 and 2 would yield the products VH1:VL2 and VH2:VL1 in
addition to VH1:VL1 and VH2:VL2.
This accessible technology for sequencing the paired VH:VL repertoire enables rapid
interrogation of the immune response and can be applied to investigate B-cell maturation,
vaccine efficacy, immune system health and autoimmunity in clinical and research settings.
The high-throughput identification and cloning of paired VH:VL antigen-specific antibodies
from responding B cells may also enable rapid generation of novel diagnostic, therapeutic or
prophylactic antibodies.
Online Methods
Preparation of microwell slides
A grid of micropillars (56-μm diameter, 50-μm height) was photolithographically patterned
onto a silica wafer using SU-8 photoresist (Fisher Scientific, Pittsburgh, PA) and the silica
wafer was used as a mold to print PDMS slides (Sylgard 184, Dow Corning, Midland, MI)
with the dimensions of a standard microscope slide and containing ∼170,000 wells each.
Molded PDMS slides were treated in an oxygen plasma chamber for 5 min to generate a
hydrophilic surface. The PDMS slides were blocked in 1% BSA for 30 min and washed with
deionized water followed by PBS to prepare for cell seeding.
Analysis of memory B-cell VH:VL pairings in response to seasonal influenza vaccination
The study was approved by the University of Chicago Institutional Review Board (IRB
09-043-A) and the University of Texas Institutional Review Board (IRB 2012-07-0002). A
healthy 30-year-old male was vaccinated with the 2010-2011 trivalent FluVirin influenza
vaccine (Novartis) and blood was drawn at day 14 after vaccination after informed consent
had been obtained. PBMCs were isolated and resuspended in DMSO/10% FCS for
cryopreservation.
Frozen PBMCs were subsequently thawed and cell suspensions were stained in PBS/0.2%
BSA with anti-human CD19 (HIB19, BioLegend, San Diego, CA), CD27 (O323,
BioLegend), CD38 (HIT2, BioLegend) and CD3 (7D6, Invitrogen, Grand Island, NY).
CD19+CD3−CD27+CD38int memory B cells were sorted using a FACSAria II sorter system
(BD Biosciences, San Diego, CA). Cells were either cryopreserved in DMSO/10% FCS for
subsequent high-throughput VH: VL pairing or single-cell sorted into 96-well plates
containing RNAse Inhibitor Cocktail (Promega, Madison, WI) and 10 mM Tris-HCl pH 8.0
for single-cell RT-PCR analysis. cDNA was synthesized from single-sorted cells using the
Maxima First Strand cDNA Synthesis Kit (Fermentas, Waltham, MA) followed by
amplification of the immunoglobulin variable genes using primer sets and PCR conditions
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previously described11. Variable genes were determined with in-house analysis software
using the IMGT search engine24.
Memory B cells frozen for high-throughput VH:VL pairing were thawed and recovered by
centrifugation at 250g for 10 min. Cells were resuspended in 200 μl RPMI-1640
supplemented with 1× GlutaMAX, 1× non-essential amino acids, 1× sodium pyruvate and
1× penicillin/streptomycin (Life Technologies) and incubated at 37 °C for 13 h in a 96-well
plate. Recovered cells were centrifuged again at 250g for 10 min and resuspended in 400 μl
PBS, and 6 μl were withdrawn for cell counting with a hemocytometer. Approximately
8,800 cells were recovered from frozen stock. Memory B cells were then spiked with ∼880
IM-9 cells (ATCC number CCL-159) as an internal control. Cells were resuspended over
two PDMS microwell slides (340,000 wells) and allowed to settle into wells by gravity over
the course of 5 min with gentle agitation. The cell seeding process has been calculated to be
90% efficient by measuring cell concentration in seeding buffers both pre- and post- cell
seeding; thus 8,000 primary cells were analyzed in this experiment. The fraction of cells
isolated in the single and multiple cell per well states was calculated using Poisson statistics
where k equals the number of cells in a single microwell and μ is the average number of
cells per well, so that the 1:39 cell:well ratio used in this experiment corresponds to 98.7%
of cells deposited at an occupancy of one cell/well. We resuspended 25 μl of poly(dT)
magnetic beads (Invitrogen mRNA Direct Kit) in 50 μl PBS and distributed over each
PDMS slide surface, (mean of 55 poly(dT) beads per well). Magnetic beads were allowed to
settle into wells by gravity for ∼5 min, then a BSA-blocked dialysis membrane (12,000–
14,000 MWCO regenerated cellulose, 25-mm flat width, Fisher Scientific) that had been
rinsed in PBS was laid over each slide surface, sealing the microwells and trapped cells and
beads inside. Excess PBS was removed from the slide and membrane surfaces using a 200
μL pipette. 500 μL of cell lysis solution (500 mM LiCl in 100 mM TRIS buffer (pH 7.5)
with 1% lithium dodecyl sulfate, 10 mM EDTA and 5 mM DTT) was applied to the dialysis
membranes for 20 min at room temperature. Time-lapse microscopy revealed that all cells
are fully lysed within 1 min (Supplementary Video 1). Subsequently the slides were
incubated at 4 °C for 10 min at which point a Dynal MPC-S magnet was placed underneath
the PDMS microwell device to hold magnetic beads inside the microwells as the dialysis
membrane was removed with forceps and discarded. Working quickly, the PDMS slides
were sequentially inverted in a Petri dish containing 2 mL of cold lysis solution and the
magnet was applied underneath the Petri dish to force the beads out of the microwells.
Subsequently, 1 ml aliquots of the lysis solution containing resuspended beads were placed
into Eppendorf tubes and beads were pelleted on a Dynal MPC-S magnetic rack and washed
once without resuspension using 1 mL per tube of wash buffer 1 (100 mM Tris, pH 7.5, 500
mM LiCl, 1 mM EDTA, 4 °C). Beads were resuspended in wash buffer 1, pelleted and
resuspended in wash buffer 2 (20 mM Tris, pH 7.5, 50 mM KCl, 3 mM MgCl) and pelleted
again. Finally beads were suspended in 2.85 mL cold RT-PCR mixture (Quanta OneStep
Fast, VWR) containing 0.05 wt% BSA (Invitrogen Ultrapure BSA, 50 mg/mL) and primer
sets for VH and VL linkage amplification (Supplementary Fig. 1 and Supplementary Table
5)3,25. The suspension containing the poly(dT) magnetic beads was added dropwise to a
stirring IKA dispersing tube (DT-20, VWR) containing 9 mL chilled oil phase (molecular
biology grade mineral oil with 4.5% Span-80, 0.4% Tween 80, 0.05% Triton X-100, v/v%,
Sigma-Aldrich, St. Louis, MO), and the mixture was agitated for 5 min at low speed. The
resulting emulsion was added to 96-well PCR plates with 100 μL emulsion per well and
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placed in a thermocycler. The RT step was performed under the following conditions: 30
min at 55 °C, followed by 2 min at 94 °C. PCR amplification was performed under the
following conditions: four cycles of 94 °C for 30 s denature, 50 °C for 30 s anneal, 72 °C for
2 min extend; four cycles of 94 °C for 30 s denature, 55 °C for 30 s anneal, 72 °C for 2 min
extend; 22 cycles of 94 °C for 30 s denature, 60 °C for 30 s anneal, 72 °C for 2 min extend;
then a final extension step for 7 min at 72 °C. After thermal cycling the emulsion was
visually inspected to ensure the absence of a bulk water phase, which is a key indicator of
emulsion stability. Following visual verification, the emulsion was collected and centrifuged
at room temperature for 10 min at 16,000g, the mineral oil upper phase was discarded, and
1.5 mL diethyl ether was added to extract the remaining oil phase and break the emulsion.
The upper ether layer was discarded, two more ether extractions were performed and
residual ether was removed in a SpeedVac for 25 min at room temperature. The aqueous
phase was diluted 5:1 in DNA binding buffer and passed through a silica spin column (DNA
Clean & Concentrator, Zymo Research, Irvine, CA) to capture the cDNA product. The
column was washed twice with 300 μL wash buffer (Zymo Research Corp) and cDNA was
eluted into 40 μL nuclease-free water. Finally, a nested PCR amplification was performed
(ThermoPol PCR buffer with Taq Polymerase, New England Biosciences, Ipswich, MA) in
a total volume of 200 μL using 4 μL of eluted cDNA as template with 400 nM primers
(Supplementary Table 6) under the following conditions: 2 min initial denaturation at 94 °C,
denaturation at 94 °C for 30 s for 39 cycles, annealing at 62 °C for 30 s and extension at 72
°C for 20 s, final extension at 72 °C for 7 min. The approximately 850 bp linked product
was extracted by agarose gel electrophoresis and sequenced using the 2 × 250 paired end
MiSeq NextGen platform (Illumina, San Diego, CA).
Analysis of plasmablast VH:VL pairings in response to TT vaccination
One female donor underwent booster immunization against TT/diphtheria toxoid (TD, 20
I.E. TT and 2 I.E. diphtheria toxoid, Sanofi Pasteur Merck Sharpe & Dohme GmbH,
Leimen, Germany) after informed consent by the Charité Universitätsmedizin Berlin had
been obtained (samples were anonymously coded and study approved by the hospital's
ethical approval board, number EA1/178/11, and the University of Texas at Austin
Institutional Review Board, IRB# 2011-11-0095). At 7 d post TT immunization, EDTA
blood was withdrawn and PBMC isolated by density gradient separation as described26.
PBMCs were stained in PBS/BSA at 4 °C for 15 min with anti-human CD3/CD14-PacB
(clones UCHT1 and M5E2, respectively, Becton Dickinson, BD), CD19-PECy7 (clone
SJ25C1, BD), CD27-Cy5 (clone 2E4, kind gift from René van Lier, Academic Medical
Centre, University of Amsterdam, The Netherlands, labeled at the Deutsches
Rheumaforschungszentrum (DRFZ), Berlin), CD20-PacO (clone HI47, Invitrogen), IgD-
PerCpCy5.5 (clone L27, BD), CD38-PE (clone HIT2, BD) and TT-Digoxigenin (labeled at
the DRFZ) for 15 min at 4 °C. Cells were washed and a second staining was performed with
anti-Digoxigenin-FITC (Roche, labeled at the DRFZ) and DAPI was added before sorting.
CD19+CD3−CD14−CD38++CD27++CD20−TT+ plasmablasts were sorted using a FACSAria
II sorter system (BD Biosciences). A portion of sorted cells were washed and cryopreserved
in DMSO/10%FCS for high-throughput VH:VL pairing.
One vial containing approximately 2,000 frozen TT+ plasmablasts was thawed and
recovered by centrifugation at 250g for 10 min, for which 20–30% recovery was
anticipated27. Cells were resuspended in 300 μL RPMI-1640 supplemented with 10% FBS,
1× GlutaMAX, 1× non-essential amino acids, 1× sodium pyruvate and 1× penicillin/
streptomycin (all from Life Technologies) and incubated at 37 °C for 13 h in a 96-well plate.
Recovered cells were centrifuged again at 250g for 10 min and resuspended in 400 μL PBS,
and 6 μL were withdrawn for cell counting with a hemocytometer. Cells were spiked with
approximately 30 ARH-77 cells as an internal control (ATCC number CRL-1621) and
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VH:VL transcripts were linked as described above, omitting IgM primers and using a 38-
cycle nested PCR; the resulting product was submitted for 2 × 250 MiSeq sequencing. VH
and VL chains were also amplified individually to obtain full VH and VL sequences for
antibody expression. Nested PCR product was diluted 1:9 and 0.5 μL were used as template
in a PCR reaction with the following conditions: 400 nM primers (Supplementary Table 7),
2 min initial denaturation at 94 °C, denaturation at 94 °C for 30 s for 12 cycles, annealing at
62 °C for 30 s and extension at 72 °C for 15 s, final extension at 72 °C for 7 min. The
resulting ∼450 bp VH or ∼400 bp VL products were purified by agarose gel electrophoresis
and submitted for 2 × 250 MiSeq sequencing.
Ten VH and VL pairs (Supplementary Data, .fna file) were selected from TT+ plasmablast
pairings and cloned into the human IgG expression vectors pMAZ-VH and pMAZ-VL,
respectively28. 40 μg each of circularized ligation product were co-transfected into
HEK293F cells (Invitrogen, NY, USA). Medium was harvested 6 d after transfection by
centrifugation and IgG was purified by a protein-A agarose (Pierce, IL, USA)
chromatography column.
Antigen affinities were determined by competitive ELISA29 using different concentrations
of IgG in a serial dilution of antigen, ranging from 100 nM to 0.05 nM in the presence of 1%
milk in PBS. Plates were coated overnight at 4 °C with 10 μg/mL of TT in 50 mM carbonate
buffer, pH 9.6, washed three times in PBST (PBS with 0.1% Tween 20) and blocked with
2% milk in PBS for 2 h at room temperature. Pre-equilibrated samples of IgG with TT
antigen were added to the blocked ELISA plate, incubated for 1 h at room temperature, and
plates were washed 3× with PBST and incubated with 50 μl of anti-human kappa light
chain-HRP secondary antibody (1:5,000, 2% milk in PBS) for ∼2 min, 25 °C. Plates were
washed 3× with PBST, then 50 μl Ultra TMB substrate (Thermo Scientific, Rockford, IL)
was added to each well and incubated at 25 °C for 5 min. Reactions were stopped using
equal volume of 1M H2SO4 and absorbance was read at 450 nm (BioTek, Winooski, VT).
Each competitive ELISA replicate was fit using a four-parameter logistic (4PL) equation,
with error represented as the s.d. of 2–3 replicates for each IgG analyzed.
Analysis of IgG+ class switched cells in healthy donor peripheral blood
PBMC from two different anonymous healthy donors (Texas Gulf Coast Regional Blood
Center) were isolated from whole blood using Histopaque-1077 centrifugation gradient
(Sigma-Aldrich) according to manufacturer protocols. 3.8 × 108 PBMCs were used as input
for cell purification using a IgG+ Memory B Cell Isolation Kit (Miltenyi Biotec, Auburn,
CA). Approximately 68,000 cells (Fig. 2a) or 52,000 cells (Supplementary Fig. 2) were
spiked with 4% IM-9 immortalized B lymphoblast cells (ATCC number CCL-159) and
seeded onto four or three PMS microwell slides, respectively, at a 1:10 cell/well ratio
corresponding to 95.1% of cells isolated as single cells by Poisson distribution. Cell seeding
was calculated to be 90% efficient and thus 61,000 cells (Fig. 2a and Supplementary Table
1) or 47,000 cells (Supplementary Fig. 2 and Supplementary Table 2) were analyzed. VH:VL
chains were paired and amplified as above using 35 nested PCR cycles and sequenced on the
Illumina MiSeq platform.
Bioinformatic methods
Raw 2 × 250 MiSeq data were filtered for minimum Phred quality score of 20 over 50% of
nucleotides to ensure high read quality in the CDR3-containing region (approximately HC nt
65-115 or LC nt 55-100). Sequence data were submitted to the International
ImMunoGeneTics Information System (IMGT) for mapping to germline V(D)J genes30.
Sequence data were filtered for in-frame V(D)J junctions, and productive VH and V κ,λ
sequences were paired by Illumina read ID. CDR-H3 nucleotide sequences were extracted
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and clustered to 96% nt identity with terminal gaps ignored, to generate a list of unique
CDR-H3s in the data set. 96% nt identity cutoff was found to be the optimal cutoff to cluster
sequencing error in spiked control clones; the number of unique CDR-H3 sequences and
hence the number of unique V genes reported refer to the number of clusters recovered from
the sample (Supplementary Table 1 and Supplementary Table 2). Overwhelmingly, the
frequency of the top VL pair for a given Vh was observed to be greater than 90%, and the
top VL pair for each CDR-H3 was used for comparison with single-cell RT-PCR for
workflow validation (Supplementary Table 3), consensus sequence generation and paired
VH:VL expression (Table 1), and VH:VL gene family heat maps (Fig. 2 and Supplementary
Figs. 2 and 3). In the case of separate VH and VL gene amplification for complete antibody
sequencing, 2 × 250 bp reads containing the 5′ V gene FR1-CDR2 and 3′ CDR2-FR4 were
paired by Illumina read ID and consensus sequences were constructed from reads containing
the exact CDR3 of interest.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Overview of the high-throughput methodology for paired VH:VL antibody repertoire
analysis. (a) B-cell populations are sorted for desired phenotype (e.g., mBCs, memory B
cells, naive BCs, naive B cells). (b) Single cells are isolated by random settling into 125-pl
wells (56-μm diameter) printed in polydimethylsiloxane (PDMS) slides the size of a
standard microscope slide (1.7 × 105 wells/slide); 2.8-μm poly(dT) microbeads are also
added to the wells (average 55 beads/well). (c) Wells are sealed with a dialysis membrane
and equilibrated with lysis buffer to lyse cells and anneal VH and VL mRNAs to poly(dT)
beads (blue figure represents a lysed cell, orange circles depict magnetic beads, black lines
depict mRNA strands; see Supplementary Video 1). (d) Beads are recovered and emulsified
for cDNA synthesis and linkage PCR to generate an ∼850–base pair VH:VL cDNA product
(Supplementary Fig. 1). (e) Next-generation sequencing is performed to sequence the linked
strands. (f) Bioinformatic processing is used to analyze the paired VH:VL repertoire.
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Figure 2.
VH:VL gene family usage of unique CDR-H3:CDR-L3 pairs identified by high-throughput
sequencing of cell populations from three different individuals in separate experiments using
the workflow in Figure 1. (a) Healthy donor peripheral IgG+ B cells (n = 2,716 unique
CDR3 pairs). (b) Peripheral TT–specific plasmablasts, isolated 7 d post-TT immunization
(CD19+CD3−CD14−CD38++CD27++CD20−TT+, n = 86 unique pairs). (c) Peripheral
memory B cells isolated 14 d after influenza vaccination (CD19+CD3−CD27+CD38int, n =
240 unique pairs). Each panel presents data from an independent experiment obtained from
61,000 fresh B cells (a), ∼400 frozen/thawed plasmablasts (b) and 8,000 twice frozen/
thawed memory B cells (c). Color indicates percentage of unique pairs from the sample;
repertoire statistics are reported in Supplementary Tables 1 and 4.
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Table 1
TT-binding affinities of IgG antibodies sequenced from TT+ peripheral plasmablasts
Antibody ID Gene family assignmenta Affinity (KD)
TT1 HV3-HD1-HJ6: KV3-KJ5 1.6 ± 0.1 nM
TT2 HV3-HD3-HJ4: LV3-LJ1 14 ± 3 nM
TT3 HV1-HD2-HJ4: KV3-KJ5 3.6 ± 1.8 nM
TT4 HV2-HD2-HJ4: KV1-KJ1 2.7 ± 0.3 nM
TT5 HV4-HD2-HJ6: KV2-KJ3 18 ± 4 nM
TT6 HV1-HD3-HJ4: KV1-KJ2 0.57 ± 0.03 nM
TT7 HV4-HD3-HJ4: KV1-KJ2 0.46 ± 0.01 nM
TT8 HV3-HD3-HJ4: LV8-LJ3 2.8 ± 0.3 nM
TT9 HV4-HD2-HJ4: KV1-KJ1 0.10 ± 0.01 nM
TT10 HV1-HD3-HJ5: KV3-KJ5 1.6 ± 0.1 nM
Peripheral blood mononuclear cells were isolated from one healthy volunteer 7 d after TT boost immunization and TT-binding
CD19+CD3−CD14−CD38++CD27++CD20− cells were sorted and analyzed as in Figure 1. Genes encoding ten of the sequenced VH:VL pairs
were cloned into an IgG expression vector and expressed transiently in HEK293F cells. TT-binding affinities of the resulting IgG were calculated
from competitive ELISA dilution curves.
a
Each heavy and light chain was distinct (Supplementary Data).
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